AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmentAstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this Share XAZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmenthttps://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/
NICE backs funding for AZ’s Lynparza ovarian cancer maintenance therapyNICE has recommended interim funding on England’s NHS for AstraZeneca’s ovarian cancer drug Lynparza in the earlier stages Share XNICE backs funding for AZ’s Lynparza ovarian cancer maintenance therapyhttps://pharmaphorum.com/news/nice-backs-funding-for-azs-lynparza-ovarian-cancer-maintenance-therapy/
AZ says recovery to continue to despite patent expiry and Brexit headwindsAstraZeneca has upped its revenue expectations following a strong second quarter, saying that sales of newer drugs will Share XAZ says recovery to continue to despite patent expiry and Brexit headwindshttps://pharmaphorum.com/news/az-says-recovery-to-continue-to-despite-patent-expiry-and-brexit-headwinds/
Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerGlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid Share XRelief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerhttps://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/
Lynparza on cusp of approval for advanced ovarian cancerBreast cancer drug Lynparza (olaparib) is poised for EU approval for the first-line treatment of a certain type Share XLynparza on cusp of approval for advanced ovarian cancerhttps://pharmaphorum.com/news/lynparza-on-cusp-of-approval-for-advanced-ovarian-cancer/
Merck and Pfizer stop third Bavencio ovarian cancer trialMerck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced Share XMerck and Pfizer stop third Bavencio ovarian cancer trialhttps://pharmaphorum.com/news/merck-and-pfizer-stop-third-bavencio-ovarian-cancer-trial/
AZ/Merck & Co get new US use for ovarian cancer drugAfter several disappointments this year AstraZeneca has ended 2018 on a positive note, gaining a new use for Share XAZ/Merck & Co get new US use for ovarian cancer drughttps://pharmaphorum.com/news/astrazeneca-merck-lynparza-roxadustat/
US regulator grants fast review for AZ ovarian cancer drugThe US Food and Drug Administration (FDA) has granted AstraZeneca priority review for its ovarian cancer drug Lynparza Share XUS regulator grants fast review for AZ ovarian cancer drughttps://pharmaphorum.com/news/us-regulator-grants-fast-review-for-az-ovarian-cancer-drug/
ESMO round-up: Big win for AstraZeneca in ovarian cancer, and moreSeveral drugmakers announced significant trial findings at this week’s European Society for Medical Oncology (ESMO) conference in Munich. Share XESMO round-up: Big win for AstraZeneca in ovarian cancer, and morehttps://pharmaphorum.com/views-and-analysis/esmo-round-up-big-win-for-astrazeneca-in-ovarian-cancer-and-more/
